QuantSignals › Forecasts › TECH
KATY's daily model path, its record on TECH, and the options read. Prices as of the Nov 10, 2026 close · page updated Nov 10, 2026.
Last close
$72.82
Nov 10, 2026 · −0.01% on the day
KATY call
SELL
run Nov 6, 2026
Path end (20 sessions)
$67.45
−7.33% from $72.78
Path range
−7.3% to −0.7%
lowest and highest point of the path
Replay record on TECH
3/15 hits
20% · 12 misses
KATY's latest public daily path for Bio-Techne, from its run on Nov 6, 2026, points down, which KATY labels SELL. Starting from the $72.78 close, the path ends 20 sessions later near $67.45 (−7.33%), around Dec 4, and ranges between −7.33% and −0.70% along the way. That is a model path, not a price target.
Since that run, TECH has closed at $72.82 on Nov 10, 2026, +0.05% from the start, 2 of 20 sessions in. So far the move runs against the path. The call is scored after session 20.
On TECH, KATY's replay record is 3 hits and 12 misses in 15 tested calls (20%), below its 50.1% rate across all tickers. Its most recent completed replay call expected −7.69% and TECH moved +0.44%: a miss on direction.
Daily closes, with KATY's Nov 6, 2026 path drawn from its start close to its end point; the shaded wedge spans the path's lowest and highest points.
The KATY apps and extension show the newest TECH path as soon as it runs, with the full step-by-step line on the chart. They are free to install; live forecasts need KATY Premium or an FST membership.
Every public TECH path this page has captured, scored on the close 20 sessions after its start: a BUY is a hit if that close is higher, a SELL if it is lower.
| Run | Call | Start close | Path end | Outcome at 20 sessions |
|---|---|---|---|---|
| Nov 6, 2026 | SELL | $72.78 | $67.45 (−7.33%) | Open, 2/20 sessions · +0.05% so far |
3 hits, 12 misses in 15 replayed TECH calls (20% on direction; 0% finished inside the 1.5% band; average path error 3.68%). Across all tickers KATY's replay hit rate is 50.1% over 1,023 calls (BUY > +1.5%, SELL < -1.5% on the 20-step path). Replays re-run the model on past data it did not see; they are not live trades.
KATY re-forecast the 20 sessions that just finished without seeing them. It expected −7.69%; the actual move was +0.44% (direction miss, average path error 4.03%).
| Step | Session | Model path | Actual close | Path vs actual |
|---|---|---|---|---|
| 1 | Oct 12, 2026 | $72.01 | $72.56 | −0.76% |
| 5 | Oct 16, 2026 | $71.05 | $72.57 | −2.09% |
| 10 | Oct 23, 2026 | $70.25 | $72.55 | −3.17% |
| 15 | Oct 30, 2026 | $68.38 | $72.66 | −5.89% |
| 20 | Nov 6, 2026 | $66.89 | $72.78 | −8.09% |
KATY's latest public daily path for TECH (run Nov 6, 2026) is SELL: from $72.78 it ends near $67.45 (−7.33%) after 20 sessions. It is a model path, not a price target. The newest path is in the KATY apps (free to install; live forecasts need KATY Premium or an FST membership).
In replay, KATY called the direction of TECH right 3 times and wrong 12 times out of 15 tested calls (20%). Public calls on this page are scored after 20 sessions and listed above, misses included.
KATY is a time-series foundation model that reads the recent daily bars of TECH and draws the most likely path for the next 20 sessions. A path that ends more than 1.5% up is a BUY, more than 1.5% down a SELL, and anything in between is NEUTRAL. It is not investment advice.
KATY draws this forecast on your own charts: in TradingView with the Chrome extension, or on your phone. The extension and apps are free to install; live forecasts need KATY Premium or an FST membership.
Healthcare & biotech
Most viewed
Not investment advice. KATY's output is a model path, not a price target and not a recommendation to buy or sell. Model forecasts are often wrong; the hit and miss counts on this page are shown so you can judge that yourself. Trading involves risk of loss. Data from QS Research; prices are daily closes and may lag.